04-739
Anti-Raf-1 Antibody, clone AM223, rabbit monoclonal
culture supernatant, clone AM223, from rabbit
Synonym(s):
Oncogene RAF1, raf proto-oncogene serine/threonine protein kinase, v-raf-1 murine leukemia viral oncogene homolog 1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
culture supernatant
clone
AM223, monoclonal
species reactivity
human, mouse, rat
technique(s)
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... RAF1(5894)
General description
The Raf proteins (Raf-1, A-Raf, B-Raf) are Ser/Thr kinases with homology to the PKC family, containing an N-terminal regulatory domain and a c-terminal catalytic domain. Members of the Raf family bind to activated Ras GTPase, which results in Raf translocation to the plasma membrane and activation. Activated Raf proteins phosphorylate MEKs, and are therefore the principle transducers of signals from Ras to MAP kinase. In addition to its role in mitogenesis, Raf-1 may play a role in regulation of apoptosis and cell cycle progression. Activation of Raf-1 involves phosphorylation of Ser338/339 and Tyr340/341. Activating mutations of B-Raf that disrupt its auto-inhibition loop have been implicated in a number of cancers, including melanoma and colon cancer.
Specificity
Predicted to cross-react with rat based on sequence homology.
Recognizes Raf-1, Mr 74 kDa.
Immunogen
Epitope: C-terminus
KLH-conjugated, synthetic peptide corresponding to the C-terminus (amino acids 637-648 (CTLTTSPRLPVF)) of human Raf-1.
Application
Anti-Raf-1 Antibody, clone AM223 is an antibody against Raf-1 for use in IP & WB.
Research Category
Signaling
Signaling
Research Sub Category
MAP Kinases
MAP Kinases
Western Blotting Analysis:
A 1:500-1:2,000 diltuoin of this lot detected Raf-1 in 3T3/A31 cell lysates.
Immunoprecipitation: 2-4 μg of a previous lot immunoprecipitated Raf-1 from 400 μg of 3T3/A31 RIPA lysate.
A 1:500-1:2,000 diltuoin of this lot detected Raf-1 in 3T3/A31 cell lysates.
Immunoprecipitation: 2-4 μg of a previous lot immunoprecipitated Raf-1 from 400 μg of 3T3/A31 RIPA lysate.
Quality
Routinely evaluated by Western Blot on 3T3/A31 lysates.
Target description
74 kDa
Linkage
Replaces: 04-412
Physical form
Cultured supernatant with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at -20ºC from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Analysis Note
Control
Positive Antigen Control: Catalog #12-305, 3T3/A31 lysate. Add 2.5 μL of 2-mercapto-ethanol/100 μL of lysate and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced lysate per lane for minigels.
Positive Antigen Control: Catalog #12-305, 3T3/A31 lysate. Add 2.5 μL of 2-mercapto-ethanol/100 μL of lysate and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced lysate per lane for minigels.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Malgorzata Milewska et al.
Therapeutic advances in medical oncology, 10, 1758834017746040-1758834017746040 (2018-02-01)
The application of genomic technologies to patient tumor samples identified groups of signaling pathways which acquire activating mutations. Some cancers are dependent on these mutations and the aberrant proteins resulting from these mutations can be targeted by novel drugs which
Naomi Elster et al.
Therapeutic advances in medical oncology, 10, 1758835918778297-1758835918778297 (2018-07-20)
Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro. Our study aimed to determine the frequency of
Patrick Kwok-Shing Ng et al.
Cancer cell, 33(3), 450-462 (2018-03-14)
The functional impact of the vast majority of cancer somatic mutations remains unknown, representing a critical knowledge gap for implementing precision oncology. Here, we report the development of a moderate-throughput functional genomic platform consisting of efficient mutant generation, sensitive viability
Kelli-Ann Monaco et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(7), 2061-2073 (2020-12-24)
Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. LXH254 was profiled in biochemical, in vitro, and in vivo assays, including examining the activities of
Ying-Yan Fang et al.
Journal of neurochemistry, 146(6), 703-721 (2018-06-26)
Menopause, a risk factor for brain dysfunction in women, is characterized by neuropsychological symptoms including depression and dementia, which are closely related to alterations in different brain regions after menopause. However, little is known about the variability in pathophysiologic changes
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service